Search
Syndax's CEO talks about the company's two new launches (Revuforj and Niktimvo), both of which are tracking ahead of expectations
Michael Metzger describes the uptake of the therapies, both of which were approved in the second half of last year, and highlights a...
Sep 8
Syndax's CEO Michael Metzger talks about the approvals of Revuforj and Niktimvo, moving both into other settings, competition, and more
He describes being first to market in the menin inhibitor space and the advantage he believes that gives Syndax, and he highlights other...
Dec 16, 2024
Recapping #ASH23 with Syndax CEO Michael Metzger
Syndax's CEO reviews late breaking data on the menin inhibitor revumenib in KMT2A-rearranged leukemias and discusses axatilimab's GvHD data.
Dec 12, 2023
.png){kind=logo}
